Design Therapeutics Inc

For the period ended Mar 31, 2025. Filed May 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

DSGN$10.80+5.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Cash Flows

(in thousands)

	Three Months Ended March 31,
	2025	2024
Cash flows from operating activities
Net loss	$(17,715)	$(11,105)
Reconciliation of net loss to net cash used in operating activities:
Depreciation	159	143
Stock-based compensation	3,539	3,184
Amortization of premiums on investment securities, net	(1,060)	(1,731)
Non-cash lease expense	(4)	4
Change in operating assets and liabilities:
Prepaid expense and other assets	(1,407)	(411)
Accounts payable and other liabilities	(301)	(2,523)
Net cash used in operating activities	(16,789)	(12,439)
Cash flows from investing activities
Purchases of investment securities	(86,548)	(45,659)
Proceeds from maturities of investment securities	94,490	66,470
Purchases of property and equipment	(72)	(195)
Net cash provided by investing activities	7,870	20,616
Cash flows from financing activities
Proceeds from the exercise of stock options	23	20
Net cash provided by financing activities	23	20
Net (decrease) increase in cash and cash equivalents	(8,896)	8,197
Cash and cash equivalents at beginning of period	22,563	21,200
Cash and cash equivalents at end of period	$13,667	$29,397
Supplemental disclosures
Purchases of property and equipment included in accounts payable and accrued expenses	$54	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.